Global RNA Therapeutics and Vaccines Market Growth 2026-2032
The global RNA Therapeutics and Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
RNA therapeutics and vaccines represent a groundbreaking approach to medical interventions that leverage the unique properties of ribonucleic acid (RNA), a molecule essential for various biological processes. These approaches have gained significant attention, particularly in the fields of medicine and biotechnology.
RNA therapeutics involve using RNA molecules to treat or prevent diseases by modulating gene expression or protein production.
Types:
mRNA (messenger RNA) Therapeutics introduce synthetic mRNA into cells to instruct them to produce specific proteins. This approach has shown promise in treating genetic disorders, cancers, and other diseases.
siRNA (small interfering RNA) Therapeutics: Use short RNA molecules to interfere with the expression of specific genes, blocking the production of harmful proteins. This approach is being explored for conditions such as viral infections and certain genetic disorders.
Antisense Oligonucleotide Therapeutics: Utilize short RNA or DNA molecules to bind to target mRNA, modulating the translation of genetic information into proteins. This approach is being studied for various diseases, including neurodegenerative disorders.
RNA vaccines are a type of vaccine that uses RNA molecules to stimulate an immune response against specific pathogens, such as viruses. RNA-based therapeutics and vaccines can be developed relatively quickly compared to traditional methods. This is particularly evident in the rapid development of COVID-19 mRNA vaccines. RNA therapies can be designed with high precision to target specific genes or proteins, offering a more targeted therapeutic approach. The modular nature of RNA allows for easy adaptation to address different diseases by altering the sequence of the RNA.
RNA therapies hold promise for personalized medicine by targeting specific genetic mutations associated with individual patients" conditions. While RNA therapeutics and vaccines show great promise, ongoing research is exploring their safety, efficacy, and potential applications for a wide range of diseases beyond those addressed by current vaccines.
United States market for RNA Therapeutics and Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for RNA Therapeutics and Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for RNA Therapeutics and Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key RNA Therapeutics and Vaccines players cover Moderna, BioNTech (Pfizer), Sanofi, Novartis, CureVac, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “RNA Therapeutics and Vaccines Industry Forecast” looks at past sales and reviews total world RNA Therapeutics and Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected RNA Therapeutics and Vaccines sales for 2026 through 2032. With RNA Therapeutics and Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Therapeutics and Vaccines industry.
This Insight Report provides a comprehensive analysis of the global RNA Therapeutics and Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNA Therapeutics and Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNA Therapeutics and Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Therapeutics and Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Therapeutics and Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA Therapeutics and Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
RNA therapeutics and vaccines represent a groundbreaking approach to medical interventions that leverage the unique properties of ribonucleic acid (RNA), a molecule essential for various biological processes. These approaches have gained significant attention, particularly in the fields of medicine and biotechnology.
RNA therapeutics involve using RNA molecules to treat or prevent diseases by modulating gene expression or protein production.
Types:
mRNA (messenger RNA) Therapeutics introduce synthetic mRNA into cells to instruct them to produce specific proteins. This approach has shown promise in treating genetic disorders, cancers, and other diseases.
siRNA (small interfering RNA) Therapeutics: Use short RNA molecules to interfere with the expression of specific genes, blocking the production of harmful proteins. This approach is being explored for conditions such as viral infections and certain genetic disorders.
Antisense Oligonucleotide Therapeutics: Utilize short RNA or DNA molecules to bind to target mRNA, modulating the translation of genetic information into proteins. This approach is being studied for various diseases, including neurodegenerative disorders.
RNA vaccines are a type of vaccine that uses RNA molecules to stimulate an immune response against specific pathogens, such as viruses. RNA-based therapeutics and vaccines can be developed relatively quickly compared to traditional methods. This is particularly evident in the rapid development of COVID-19 mRNA vaccines. RNA therapies can be designed with high precision to target specific genes or proteins, offering a more targeted therapeutic approach. The modular nature of RNA allows for easy adaptation to address different diseases by altering the sequence of the RNA.
RNA therapies hold promise for personalized medicine by targeting specific genetic mutations associated with individual patients" conditions. While RNA therapeutics and vaccines show great promise, ongoing research is exploring their safety, efficacy, and potential applications for a wide range of diseases beyond those addressed by current vaccines.
United States market for RNA Therapeutics and Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for RNA Therapeutics and Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for RNA Therapeutics and Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key RNA Therapeutics and Vaccines players cover Moderna, BioNTech (Pfizer), Sanofi, Novartis, CureVac, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “RNA Therapeutics and Vaccines Industry Forecast” looks at past sales and reviews total world RNA Therapeutics and Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected RNA Therapeutics and Vaccines sales for 2026 through 2032. With RNA Therapeutics and Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Therapeutics and Vaccines industry.
This Insight Report provides a comprehensive analysis of the global RNA Therapeutics and Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNA Therapeutics and Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNA Therapeutics and Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Therapeutics and Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Therapeutics and Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA Therapeutics and Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- mRNA (messenger RNA) Therapeutics
- siRNA (small interfering RNA) Therapeutics
- Antisense Oligonucleotide Therapeutics
- Hospitals
- Research Institutions
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Moderna
- BioNTech (Pfizer)
- Sanofi
- Novartis
- CureVac
- CSL
- Arrowhead Pharmaceuticals
- Alnylam Pharmaceuticals
- GlaxoSmithKline (GSK)
- Ionis Pharmaceuticals
- Regulus Therapeutics
- Roche
- AstraZeneca
- Sarepta Therapeutics
- Orna Therapeutics
- What is the 10-year outlook for the global RNA Therapeutics and Vaccines market?
- What factors are driving RNA Therapeutics and Vaccines market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do RNA Therapeutics and Vaccines market opportunities vary by end market size?
- How does RNA Therapeutics and Vaccines break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA Therapeutics and Vaccines Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for RNA Therapeutics and Vaccines by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for RNA Therapeutics and Vaccines by Country/Region, 2021, 2025 & 2032
2.2 RNA Therapeutics and Vaccines Segment by Type
2.2.1 mRNA (messenger RNA) Therapeutics
2.2.2 siRNA (small interfering RNA) Therapeutics
2.2.3 Antisense Oligonucleotide Therapeutics
2.2.4 RNA Therapeutics and Vaccines Sales by Type
2.2.4.1 Global RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
2.2.4.2 Global RNA Therapeutics and Vaccines Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global RNA Therapeutics and Vaccines Sale Price by Type (2021-2026)
2.3 RNA Therapeutics and Vaccines Segment by Application
2.3.1 Hospitals
2.3.2 Research Institutions
2.3.3 RNA Therapeutics and Vaccines Sales by Application
2.3.3.1 Global RNA Therapeutics and Vaccines Sale Market Share by Application (2021-2026)
2.3.3.2 Global RNA Therapeutics and Vaccines Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global RNA Therapeutics and Vaccines Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global RNA Therapeutics and Vaccines Breakdown Data by Company
3.1.1 Global RNA Therapeutics and Vaccines Annual Sales by Company (2021-2026)
3.1.2 Global RNA Therapeutics and Vaccines Sales Market Share by Company (2021-2026)
3.2 Global RNA Therapeutics and Vaccines Annual Revenue by Company (2021-2026)
3.2.1 Global RNA Therapeutics and Vaccines Revenue by Company (2021-2026)
3.2.2 Global RNA Therapeutics and Vaccines Revenue Market Share by Company (2021-2026)
3.3 Global RNA Therapeutics and Vaccines Sale Price by Company
3.4 Key Manufacturers RNA Therapeutics and Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers RNA Therapeutics and Vaccines Product Location Distribution
3.4.2 Players RNA Therapeutics and Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RNA THERAPEUTICS AND VACCINES BY GEOGRAPHIC REGION
4.1 World Historic RNA Therapeutics and Vaccines Market Size by Geographic Region (2021-2026)
4.1.1 Global RNA Therapeutics and Vaccines Annual Sales by Geographic Region (2021-2026)
4.1.2 Global RNA Therapeutics and Vaccines Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic RNA Therapeutics and Vaccines Market Size by Country/Region (2021-2026)
4.2.1 Global RNA Therapeutics and Vaccines Annual Sales by Country/Region (2021-2026)
4.2.2 Global RNA Therapeutics and Vaccines Annual Revenue by Country/Region (2021-2026)
4.3 Americas RNA Therapeutics and Vaccines Sales Growth
4.4 APAC RNA Therapeutics and Vaccines Sales Growth
4.5 Europe RNA Therapeutics and Vaccines Sales Growth
4.6 Middle East & Africa RNA Therapeutics and Vaccines Sales Growth
5 AMERICAS
5.1 Americas RNA Therapeutics and Vaccines Sales by Country
5.1.1 Americas RNA Therapeutics and Vaccines Sales by Country (2021-2026)
5.1.2 Americas RNA Therapeutics and Vaccines Revenue by Country (2021-2026)
5.2 Americas RNA Therapeutics and Vaccines Sales by Type (2021-2026)
5.3 Americas RNA Therapeutics and Vaccines Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Therapeutics and Vaccines Sales by Region
6.1.1 APAC RNA Therapeutics and Vaccines Sales by Region (2021-2026)
6.1.2 APAC RNA Therapeutics and Vaccines Revenue by Region (2021-2026)
6.2 APAC RNA Therapeutics and Vaccines Sales by Type (2021-2026)
6.3 APAC RNA Therapeutics and Vaccines Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe RNA Therapeutics and Vaccines by Country
7.1.1 Europe RNA Therapeutics and Vaccines Sales by Country (2021-2026)
7.1.2 Europe RNA Therapeutics and Vaccines Revenue by Country (2021-2026)
7.2 Europe RNA Therapeutics and Vaccines Sales by Type (2021-2026)
7.3 Europe RNA Therapeutics and Vaccines Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA Therapeutics and Vaccines by Country
8.1.1 Middle East & Africa RNA Therapeutics and Vaccines Sales by Country (2021-2026)
8.1.2 Middle East & Africa RNA Therapeutics and Vaccines Revenue by Country (2021-2026)
8.2 Middle East & Africa RNA Therapeutics and Vaccines Sales by Type (2021-2026)
8.3 Middle East & Africa RNA Therapeutics and Vaccines Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of RNA Therapeutics and Vaccines
10.3 Manufacturing Process Analysis of RNA Therapeutics and Vaccines
10.4 Industry Chain Structure of RNA Therapeutics and Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 RNA Therapeutics and Vaccines Distributors
11.3 RNA Therapeutics and Vaccines Customer
12 WORLD FORECAST REVIEW FOR RNA THERAPEUTICS AND VACCINES BY GEOGRAPHIC REGION
12.1 Global RNA Therapeutics and Vaccines Market Size Forecast by Region
12.1.1 Global RNA Therapeutics and Vaccines Forecast by Region (2027-2032)
12.1.2 Global RNA Therapeutics and Vaccines Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global RNA Therapeutics and Vaccines Forecast by Type (2027-2032)
12.7 Global RNA Therapeutics and Vaccines Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Moderna
13.1.1 Moderna Company Information
13.1.2 Moderna RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.1.3 Moderna RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Moderna Main Business Overview
13.1.5 Moderna Latest Developments
13.2 BioNTech (Pfizer)
13.2.1 BioNTech (Pfizer) Company Information
13.2.2 BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.2.3 BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 BioNTech (Pfizer) Main Business Overview
13.2.5 BioNTech (Pfizer) Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.3.3 Sanofi RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.4.3 Novartis RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 CureVac
13.5.1 CureVac Company Information
13.5.2 CureVac RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.5.3 CureVac RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 CureVac Main Business Overview
13.5.5 CureVac Latest Developments
13.6 CSL
13.6.1 CSL Company Information
13.6.2 CSL RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.6.3 CSL RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CSL Main Business Overview
13.6.5 CSL Latest Developments
13.7 Arrowhead Pharmaceuticals
13.7.1 Arrowhead Pharmaceuticals Company Information
13.7.2 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.7.3 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Arrowhead Pharmaceuticals Main Business Overview
13.7.5 Arrowhead Pharmaceuticals Latest Developments
13.8 Alnylam Pharmaceuticals
13.8.1 Alnylam Pharmaceuticals Company Information
13.8.2 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.8.3 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Alnylam Pharmaceuticals Main Business Overview
13.8.5 Alnylam Pharmaceuticals Latest Developments
13.9 GlaxoSmithKline (GSK)
13.9.1 GlaxoSmithKline (GSK) Company Information
13.9.2 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.9.3 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 GlaxoSmithKline (GSK) Main Business Overview
13.9.5 GlaxoSmithKline (GSK) Latest Developments
13.10 Ionis Pharmaceuticals
13.10.1 Ionis Pharmaceuticals Company Information
13.10.2 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.10.3 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Ionis Pharmaceuticals Main Business Overview
13.10.5 Ionis Pharmaceuticals Latest Developments
13.11 Regulus Therapeutics
13.11.1 Regulus Therapeutics Company Information
13.11.2 Regulus Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.11.3 Regulus Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Regulus Therapeutics Main Business Overview
13.11.5 Regulus Therapeutics Latest Developments
13.12 Roche
13.12.1 Roche Company Information
13.12.2 Roche RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.12.3 Roche RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Roche Main Business Overview
13.12.5 Roche Latest Developments
13.13 AstraZeneca
13.13.1 AstraZeneca Company Information
13.13.2 AstraZeneca RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.13.3 AstraZeneca RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 AstraZeneca Main Business Overview
13.13.5 AstraZeneca Latest Developments
13.14 Sarepta Therapeutics
13.14.1 Sarepta Therapeutics Company Information
13.14.2 Sarepta Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.14.3 Sarepta Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sarepta Therapeutics Main Business Overview
13.14.5 Sarepta Therapeutics Latest Developments
13.15 Orna Therapeutics
13.15.1 Orna Therapeutics Company Information
13.15.2 Orna Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.15.3 Orna Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Orna Therapeutics Main Business Overview
13.15.5 Orna Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA Therapeutics and Vaccines Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for RNA Therapeutics and Vaccines by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for RNA Therapeutics and Vaccines by Country/Region, 2021, 2025 & 2032
2.2 RNA Therapeutics and Vaccines Segment by Type
2.2.1 mRNA (messenger RNA) Therapeutics
2.2.2 siRNA (small interfering RNA) Therapeutics
2.2.3 Antisense Oligonucleotide Therapeutics
2.2.4 RNA Therapeutics and Vaccines Sales by Type
2.2.4.1 Global RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
2.2.4.2 Global RNA Therapeutics and Vaccines Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global RNA Therapeutics and Vaccines Sale Price by Type (2021-2026)
2.3 RNA Therapeutics and Vaccines Segment by Application
2.3.1 Hospitals
2.3.2 Research Institutions
2.3.3 RNA Therapeutics and Vaccines Sales by Application
2.3.3.1 Global RNA Therapeutics and Vaccines Sale Market Share by Application (2021-2026)
2.3.3.2 Global RNA Therapeutics and Vaccines Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global RNA Therapeutics and Vaccines Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global RNA Therapeutics and Vaccines Breakdown Data by Company
3.1.1 Global RNA Therapeutics and Vaccines Annual Sales by Company (2021-2026)
3.1.2 Global RNA Therapeutics and Vaccines Sales Market Share by Company (2021-2026)
3.2 Global RNA Therapeutics and Vaccines Annual Revenue by Company (2021-2026)
3.2.1 Global RNA Therapeutics and Vaccines Revenue by Company (2021-2026)
3.2.2 Global RNA Therapeutics and Vaccines Revenue Market Share by Company (2021-2026)
3.3 Global RNA Therapeutics and Vaccines Sale Price by Company
3.4 Key Manufacturers RNA Therapeutics and Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers RNA Therapeutics and Vaccines Product Location Distribution
3.4.2 Players RNA Therapeutics and Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RNA THERAPEUTICS AND VACCINES BY GEOGRAPHIC REGION
4.1 World Historic RNA Therapeutics and Vaccines Market Size by Geographic Region (2021-2026)
4.1.1 Global RNA Therapeutics and Vaccines Annual Sales by Geographic Region (2021-2026)
4.1.2 Global RNA Therapeutics and Vaccines Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic RNA Therapeutics and Vaccines Market Size by Country/Region (2021-2026)
4.2.1 Global RNA Therapeutics and Vaccines Annual Sales by Country/Region (2021-2026)
4.2.2 Global RNA Therapeutics and Vaccines Annual Revenue by Country/Region (2021-2026)
4.3 Americas RNA Therapeutics and Vaccines Sales Growth
4.4 APAC RNA Therapeutics and Vaccines Sales Growth
4.5 Europe RNA Therapeutics and Vaccines Sales Growth
4.6 Middle East & Africa RNA Therapeutics and Vaccines Sales Growth
5 AMERICAS
5.1 Americas RNA Therapeutics and Vaccines Sales by Country
5.1.1 Americas RNA Therapeutics and Vaccines Sales by Country (2021-2026)
5.1.2 Americas RNA Therapeutics and Vaccines Revenue by Country (2021-2026)
5.2 Americas RNA Therapeutics and Vaccines Sales by Type (2021-2026)
5.3 Americas RNA Therapeutics and Vaccines Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Therapeutics and Vaccines Sales by Region
6.1.1 APAC RNA Therapeutics and Vaccines Sales by Region (2021-2026)
6.1.2 APAC RNA Therapeutics and Vaccines Revenue by Region (2021-2026)
6.2 APAC RNA Therapeutics and Vaccines Sales by Type (2021-2026)
6.3 APAC RNA Therapeutics and Vaccines Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe RNA Therapeutics and Vaccines by Country
7.1.1 Europe RNA Therapeutics and Vaccines Sales by Country (2021-2026)
7.1.2 Europe RNA Therapeutics and Vaccines Revenue by Country (2021-2026)
7.2 Europe RNA Therapeutics and Vaccines Sales by Type (2021-2026)
7.3 Europe RNA Therapeutics and Vaccines Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA Therapeutics and Vaccines by Country
8.1.1 Middle East & Africa RNA Therapeutics and Vaccines Sales by Country (2021-2026)
8.1.2 Middle East & Africa RNA Therapeutics and Vaccines Revenue by Country (2021-2026)
8.2 Middle East & Africa RNA Therapeutics and Vaccines Sales by Type (2021-2026)
8.3 Middle East & Africa RNA Therapeutics and Vaccines Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of RNA Therapeutics and Vaccines
10.3 Manufacturing Process Analysis of RNA Therapeutics and Vaccines
10.4 Industry Chain Structure of RNA Therapeutics and Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 RNA Therapeutics and Vaccines Distributors
11.3 RNA Therapeutics and Vaccines Customer
12 WORLD FORECAST REVIEW FOR RNA THERAPEUTICS AND VACCINES BY GEOGRAPHIC REGION
12.1 Global RNA Therapeutics and Vaccines Market Size Forecast by Region
12.1.1 Global RNA Therapeutics and Vaccines Forecast by Region (2027-2032)
12.1.2 Global RNA Therapeutics and Vaccines Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global RNA Therapeutics and Vaccines Forecast by Type (2027-2032)
12.7 Global RNA Therapeutics and Vaccines Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Moderna
13.1.1 Moderna Company Information
13.1.2 Moderna RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.1.3 Moderna RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Moderna Main Business Overview
13.1.5 Moderna Latest Developments
13.2 BioNTech (Pfizer)
13.2.1 BioNTech (Pfizer) Company Information
13.2.2 BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.2.3 BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 BioNTech (Pfizer) Main Business Overview
13.2.5 BioNTech (Pfizer) Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.3.3 Sanofi RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.4.3 Novartis RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 CureVac
13.5.1 CureVac Company Information
13.5.2 CureVac RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.5.3 CureVac RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 CureVac Main Business Overview
13.5.5 CureVac Latest Developments
13.6 CSL
13.6.1 CSL Company Information
13.6.2 CSL RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.6.3 CSL RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CSL Main Business Overview
13.6.5 CSL Latest Developments
13.7 Arrowhead Pharmaceuticals
13.7.1 Arrowhead Pharmaceuticals Company Information
13.7.2 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.7.3 Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Arrowhead Pharmaceuticals Main Business Overview
13.7.5 Arrowhead Pharmaceuticals Latest Developments
13.8 Alnylam Pharmaceuticals
13.8.1 Alnylam Pharmaceuticals Company Information
13.8.2 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.8.3 Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Alnylam Pharmaceuticals Main Business Overview
13.8.5 Alnylam Pharmaceuticals Latest Developments
13.9 GlaxoSmithKline (GSK)
13.9.1 GlaxoSmithKline (GSK) Company Information
13.9.2 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.9.3 GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 GlaxoSmithKline (GSK) Main Business Overview
13.9.5 GlaxoSmithKline (GSK) Latest Developments
13.10 Ionis Pharmaceuticals
13.10.1 Ionis Pharmaceuticals Company Information
13.10.2 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.10.3 Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Ionis Pharmaceuticals Main Business Overview
13.10.5 Ionis Pharmaceuticals Latest Developments
13.11 Regulus Therapeutics
13.11.1 Regulus Therapeutics Company Information
13.11.2 Regulus Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.11.3 Regulus Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Regulus Therapeutics Main Business Overview
13.11.5 Regulus Therapeutics Latest Developments
13.12 Roche
13.12.1 Roche Company Information
13.12.2 Roche RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.12.3 Roche RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Roche Main Business Overview
13.12.5 Roche Latest Developments
13.13 AstraZeneca
13.13.1 AstraZeneca Company Information
13.13.2 AstraZeneca RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.13.3 AstraZeneca RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 AstraZeneca Main Business Overview
13.13.5 AstraZeneca Latest Developments
13.14 Sarepta Therapeutics
13.14.1 Sarepta Therapeutics Company Information
13.14.2 Sarepta Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.14.3 Sarepta Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sarepta Therapeutics Main Business Overview
13.14.5 Sarepta Therapeutics Latest Developments
13.15 Orna Therapeutics
13.15.1 Orna Therapeutics Company Information
13.15.2 Orna Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
13.15.3 Orna Therapeutics RNA Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Orna Therapeutics Main Business Overview
13.15.5 Orna Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. RNA Therapeutics and Vaccines Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. RNA Therapeutics and Vaccines Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of mRNA (messenger RNA) Therapeutics
Table 4. Major Players of siRNA (small interfering RNA) Therapeutics
Table 5. Major Players of Antisense Oligonucleotide Therapeutics
Table 6. Global RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 7. Global RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Table 8. Global RNA Therapeutics and Vaccines Revenue by Type (2021-2026) & ($ million)
Table 9. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2021-2026)
Table 10. Global RNA Therapeutics and Vaccines Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global RNA Therapeutics and Vaccines Sale by Application (2021-2026) & (K Units)
Table 12. Global RNA Therapeutics and Vaccines Sale Market Share by Application (2021-2026)
Table 13. Global RNA Therapeutics and Vaccines Revenue by Application (2021-2026) & ($ million)
Table 14. Global RNA Therapeutics and Vaccines Revenue Market Share by Application (2021-2026)
Table 15. Global RNA Therapeutics and Vaccines Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global RNA Therapeutics and Vaccines Sales by Company (2021-2026) & (K Units)
Table 17. Global RNA Therapeutics and Vaccines Sales Market Share by Company (2021-2026)
Table 18. Global RNA Therapeutics and Vaccines Revenue by Company (2021-2026) & ($ millions)
Table 19. Global RNA Therapeutics and Vaccines Revenue Market Share by Company (2021-2026)
Table 20. Global RNA Therapeutics and Vaccines Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers RNA Therapeutics and Vaccines Producing Area Distribution and Sales Area
Table 22. Players RNA Therapeutics and Vaccines Products Offered
Table 23. RNA Therapeutics and Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global RNA Therapeutics and Vaccines Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global RNA Therapeutics and Vaccines Sales Market Share Geographic Region (2021-2026)
Table 28. Global RNA Therapeutics and Vaccines Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global RNA Therapeutics and Vaccines Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global RNA Therapeutics and Vaccines Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global RNA Therapeutics and Vaccines Sales Market Share by Country/Region (2021-2026)
Table 32. Global RNA Therapeutics and Vaccines Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global RNA Therapeutics and Vaccines Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas RNA Therapeutics and Vaccines Sales by Country (2021-2026) & (K Units)
Table 35. Americas RNA Therapeutics and Vaccines Sales Market Share by Country (2021-2026)
Table 36. Americas RNA Therapeutics and Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 38. Americas RNA Therapeutics and Vaccines Sales by Application (2021-2026) & (K Units)
Table 39. APAC RNA Therapeutics and Vaccines Sales by Region (2021-2026) & (K Units)
Table 40. APAC RNA Therapeutics and Vaccines Sales Market Share by Region (2021-2026)
Table 41. APAC RNA Therapeutics and Vaccines Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 43. APAC RNA Therapeutics and Vaccines Sales by Application (2021-2026) & (K Units)
Table 44. Europe RNA Therapeutics and Vaccines Sales by Country (2021-2026) & (K Units)
Table 45. Europe RNA Therapeutics and Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 47. Europe RNA Therapeutics and Vaccines Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa RNA Therapeutics and Vaccines Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa RNA Therapeutics and Vaccines Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa RNA Therapeutics and Vaccines Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of RNA Therapeutics and Vaccines
Table 53. Key Market Challenges & Risks of RNA Therapeutics and Vaccines
Table 54. Key Industry Trends of RNA Therapeutics and Vaccines
Table 55. RNA Therapeutics and Vaccines Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. RNA Therapeutics and Vaccines Distributors List
Table 58. RNA Therapeutics and Vaccines Customer List
Table 59. Global RNA Therapeutics and Vaccines Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global RNA Therapeutics and Vaccines Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas RNA Therapeutics and Vaccines Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas RNA Therapeutics and Vaccines Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC RNA Therapeutics and Vaccines Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC RNA Therapeutics and Vaccines Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe RNA Therapeutics and Vaccines Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe RNA Therapeutics and Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa RNA Therapeutics and Vaccines Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa RNA Therapeutics and Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global RNA Therapeutics and Vaccines Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global RNA Therapeutics and Vaccines Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global RNA Therapeutics and Vaccines Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global RNA Therapeutics and Vaccines Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Moderna Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 74. Moderna RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 75. Moderna RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Moderna Main Business
Table 77. Moderna Latest Developments
Table 78. BioNTech (Pfizer) Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 80. BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. BioNTech (Pfizer) Main Business
Table 82. BioNTech (Pfizer) Latest Developments
Table 83. Sanofi Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Sanofi RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 85. Sanofi RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Sanofi Main Business
Table 87. Sanofi Latest Developments
Table 88. Novartis Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. Novartis RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 90. Novartis RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Novartis Main Business
Table 92. Novartis Latest Developments
Table 93. CureVac Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. CureVac RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 95. CureVac RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. CureVac Main Business
Table 97. CureVac Latest Developments
Table 98. CSL Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. CSL RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 100. CSL RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. CSL Main Business
Table 102. CSL Latest Developments
Table 103. Arrowhead Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 105. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Arrowhead Pharmaceuticals Main Business
Table 107. Arrowhead Pharmaceuticals Latest Developments
Table 108. Alnylam Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 110. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Alnylam Pharmaceuticals Main Business
Table 112. Alnylam Pharmaceuticals Latest Developments
Table 113. GlaxoSmithKline (GSK) Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 115. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. GlaxoSmithKline (GSK) Main Business
Table 117. GlaxoSmithKline (GSK) Latest Developments
Table 118. Ionis Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 120. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Ionis Pharmaceuticals Main Business
Table 122. Ionis Pharmaceuticals Latest Developments
Table 123. Regulus Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. Regulus Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 125. Regulus Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Regulus Therapeutics Main Business
Table 127. Regulus Therapeutics Latest Developments
Table 128. Roche Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 129. Roche RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 130. Roche RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Roche Main Business
Table 132. Roche Latest Developments
Table 133. AstraZeneca Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 134. AstraZeneca RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 135. AstraZeneca RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. AstraZeneca Main Business
Table 137. AstraZeneca Latest Developments
Table 138. Sarepta Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 139. Sarepta Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 140. Sarepta Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Sarepta Therapeutics Main Business
Table 142. Sarepta Therapeutics Latest Developments
Table 143. Orna Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 144. Orna Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 145. Orna Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Orna Therapeutics Main Business
Table 147. Orna Therapeutics Latest Developments
Table 1. RNA Therapeutics and Vaccines Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. RNA Therapeutics and Vaccines Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of mRNA (messenger RNA) Therapeutics
Table 4. Major Players of siRNA (small interfering RNA) Therapeutics
Table 5. Major Players of Antisense Oligonucleotide Therapeutics
Table 6. Global RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 7. Global RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Table 8. Global RNA Therapeutics and Vaccines Revenue by Type (2021-2026) & ($ million)
Table 9. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2021-2026)
Table 10. Global RNA Therapeutics and Vaccines Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global RNA Therapeutics and Vaccines Sale by Application (2021-2026) & (K Units)
Table 12. Global RNA Therapeutics and Vaccines Sale Market Share by Application (2021-2026)
Table 13. Global RNA Therapeutics and Vaccines Revenue by Application (2021-2026) & ($ million)
Table 14. Global RNA Therapeutics and Vaccines Revenue Market Share by Application (2021-2026)
Table 15. Global RNA Therapeutics and Vaccines Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global RNA Therapeutics and Vaccines Sales by Company (2021-2026) & (K Units)
Table 17. Global RNA Therapeutics and Vaccines Sales Market Share by Company (2021-2026)
Table 18. Global RNA Therapeutics and Vaccines Revenue by Company (2021-2026) & ($ millions)
Table 19. Global RNA Therapeutics and Vaccines Revenue Market Share by Company (2021-2026)
Table 20. Global RNA Therapeutics and Vaccines Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers RNA Therapeutics and Vaccines Producing Area Distribution and Sales Area
Table 22. Players RNA Therapeutics and Vaccines Products Offered
Table 23. RNA Therapeutics and Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global RNA Therapeutics and Vaccines Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global RNA Therapeutics and Vaccines Sales Market Share Geographic Region (2021-2026)
Table 28. Global RNA Therapeutics and Vaccines Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global RNA Therapeutics and Vaccines Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global RNA Therapeutics and Vaccines Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global RNA Therapeutics and Vaccines Sales Market Share by Country/Region (2021-2026)
Table 32. Global RNA Therapeutics and Vaccines Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global RNA Therapeutics and Vaccines Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas RNA Therapeutics and Vaccines Sales by Country (2021-2026) & (K Units)
Table 35. Americas RNA Therapeutics and Vaccines Sales Market Share by Country (2021-2026)
Table 36. Americas RNA Therapeutics and Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 38. Americas RNA Therapeutics and Vaccines Sales by Application (2021-2026) & (K Units)
Table 39. APAC RNA Therapeutics and Vaccines Sales by Region (2021-2026) & (K Units)
Table 40. APAC RNA Therapeutics and Vaccines Sales Market Share by Region (2021-2026)
Table 41. APAC RNA Therapeutics and Vaccines Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 43. APAC RNA Therapeutics and Vaccines Sales by Application (2021-2026) & (K Units)
Table 44. Europe RNA Therapeutics and Vaccines Sales by Country (2021-2026) & (K Units)
Table 45. Europe RNA Therapeutics and Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 47. Europe RNA Therapeutics and Vaccines Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa RNA Therapeutics and Vaccines Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa RNA Therapeutics and Vaccines Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa RNA Therapeutics and Vaccines Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa RNA Therapeutics and Vaccines Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of RNA Therapeutics and Vaccines
Table 53. Key Market Challenges & Risks of RNA Therapeutics and Vaccines
Table 54. Key Industry Trends of RNA Therapeutics and Vaccines
Table 55. RNA Therapeutics and Vaccines Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. RNA Therapeutics and Vaccines Distributors List
Table 58. RNA Therapeutics and Vaccines Customer List
Table 59. Global RNA Therapeutics and Vaccines Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global RNA Therapeutics and Vaccines Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas RNA Therapeutics and Vaccines Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas RNA Therapeutics and Vaccines Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC RNA Therapeutics and Vaccines Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC RNA Therapeutics and Vaccines Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe RNA Therapeutics and Vaccines Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe RNA Therapeutics and Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa RNA Therapeutics and Vaccines Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa RNA Therapeutics and Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global RNA Therapeutics and Vaccines Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global RNA Therapeutics and Vaccines Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global RNA Therapeutics and Vaccines Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global RNA Therapeutics and Vaccines Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Moderna Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 74. Moderna RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 75. Moderna RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Moderna Main Business
Table 77. Moderna Latest Developments
Table 78. BioNTech (Pfizer) Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. BioNTech (Pfizer) RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 80. BioNTech (Pfizer) RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. BioNTech (Pfizer) Main Business
Table 82. BioNTech (Pfizer) Latest Developments
Table 83. Sanofi Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Sanofi RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 85. Sanofi RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Sanofi Main Business
Table 87. Sanofi Latest Developments
Table 88. Novartis Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. Novartis RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 90. Novartis RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Novartis Main Business
Table 92. Novartis Latest Developments
Table 93. CureVac Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. CureVac RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 95. CureVac RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. CureVac Main Business
Table 97. CureVac Latest Developments
Table 98. CSL Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. CSL RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 100. CSL RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. CSL Main Business
Table 102. CSL Latest Developments
Table 103. Arrowhead Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 105. Arrowhead Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Arrowhead Pharmaceuticals Main Business
Table 107. Arrowhead Pharmaceuticals Latest Developments
Table 108. Alnylam Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 110. Alnylam Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Alnylam Pharmaceuticals Main Business
Table 112. Alnylam Pharmaceuticals Latest Developments
Table 113. GlaxoSmithKline (GSK) Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 115. GlaxoSmithKline (GSK) RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. GlaxoSmithKline (GSK) Main Business
Table 117. GlaxoSmithKline (GSK) Latest Developments
Table 118. Ionis Pharmaceuticals Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 120. Ionis Pharmaceuticals RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Ionis Pharmaceuticals Main Business
Table 122. Ionis Pharmaceuticals Latest Developments
Table 123. Regulus Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. Regulus Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 125. Regulus Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Regulus Therapeutics Main Business
Table 127. Regulus Therapeutics Latest Developments
Table 128. Roche Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 129. Roche RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 130. Roche RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Roche Main Business
Table 132. Roche Latest Developments
Table 133. AstraZeneca Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 134. AstraZeneca RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 135. AstraZeneca RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. AstraZeneca Main Business
Table 137. AstraZeneca Latest Developments
Table 138. Sarepta Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 139. Sarepta Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 140. Sarepta Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Sarepta Therapeutics Main Business
Table 142. Sarepta Therapeutics Latest Developments
Table 143. Orna Therapeutics Basic Information, RNA Therapeutics and Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 144. Orna Therapeutics RNA Therapeutics and Vaccines Product Portfolios and Specifications
Table 145. Orna Therapeutics RNA Therapeutics and Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Orna Therapeutics Main Business
Table 147. Orna Therapeutics Latest Developments
LIST OF FIGURES
Figure 1. Picture of RNA Therapeutics and Vaccines
Figure 2. RNA Therapeutics and Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global RNA Therapeutics and Vaccines Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global RNA Therapeutics and Vaccines Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. RNA Therapeutics and Vaccines Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. RNA Therapeutics and Vaccines Sales Market Share by Country/Region (2025)
Figure 10. RNA Therapeutics and Vaccines Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of mRNA (messenger RNA) Therapeutics
Figure 12. Product Picture of siRNA (small interfering RNA) Therapeutics
Figure 13. Product Picture of Antisense Oligonucleotide Therapeutics
Figure 14. Global RNA Therapeutics and Vaccines Sales Market Share by Type in 2026
Figure 15. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2021-2026)
Figure 16. RNA Therapeutics and Vaccines Consumed in Hospitals
Figure 17. Global RNA Therapeutics and Vaccines Market: Hospitals (2021-2026) & (K Units)
Figure 18. RNA Therapeutics and Vaccines Consumed in Research Institutions
Figure 19. Global RNA Therapeutics and Vaccines Market: Research Institutions (2021-2026) & (K Units)
Figure 20. Global RNA Therapeutics and Vaccines Sale Market Share by Application (2025)
Figure 21. Global RNA Therapeutics and Vaccines Revenue Market Share by Application in 2026
Figure 22. RNA Therapeutics and Vaccines Sales by Company in 2026 (K Units)
Figure 23. Global RNA Therapeutics and Vaccines Sales Market Share by Company in 2026
Figure 24. RNA Therapeutics and Vaccines Revenue by Company in 2026 ($ millions)
Figure 25. Global RNA Therapeutics and Vaccines Revenue Market Share by Company in 2026
Figure 26. Global RNA Therapeutics and Vaccines Sales Market Share by Geographic Region (2021-2026)
Figure 27. Global RNA Therapeutics and Vaccines Revenue Market Share by Geographic Region in 2026
Figure 28. Americas RNA Therapeutics and Vaccines Sales 2021-2026 (K Units)
Figure 29. Americas RNA Therapeutics and Vaccines Revenue 2021-2026 ($ millions)
Figure 30. APAC RNA Therapeutics and Vaccines Sales 2021-2026 (K Units)
Figure 31. APAC RNA Therapeutics and Vaccines Revenue 2021-2026 ($ millions)
Figure 32. Europe RNA Therapeutics and Vaccines Sales 2021-2026 (K Units)
Figure 33. Europe RNA Therapeutics and Vaccines Revenue 2021-2026 ($ millions)
Figure 34. Middle East & Africa RNA Therapeutics and Vaccines Sales 2021-2026 (K Units)
Figure 35. Middle East & Africa RNA Therapeutics and Vaccines Revenue 2021-2026 ($ millions)
Figure 36. Americas RNA Therapeutics and Vaccines Sales Market Share by Country in 2026
Figure 37. Americas RNA Therapeutics and Vaccines Revenue Market Share by Country (2021-2026)
Figure 38. Americas RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Figure 39. Americas RNA Therapeutics and Vaccines Sales Market Share by Application (2021-2026)
Figure 40. United States RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 41. Canada RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 42. Mexico RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 43. Brazil RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 44. APAC RNA Therapeutics and Vaccines Sales Market Share by Region in 2026
Figure 45. APAC RNA Therapeutics and Vaccines Revenue Market Share by Region (2021-2026)
Figure 46. APAC RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Figure 47. APAC RNA Therapeutics and Vaccines Sales Market Share by Application (2021-2026)
Figure 48. China RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 49. Japan RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 50. South Korea RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 51. Southeast Asia RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 52. India RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 53. Australia RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 54. China Taiwan RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 55. Europe RNA Therapeutics and Vaccines Sales Market Share by Country in 2026
Figure 56. Europe RNA Therapeutics and Vaccines Revenue Market Share by Country (2021-2026)
Figure 57. Europe RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Figure 58. Europe RNA Therapeutics and Vaccines Sales Market Share by Application (2021-2026)
Figure 59. Germany RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 60. France RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 61. UK RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 62. Italy RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 63. Russia RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 64. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Country (2021-2026)
Figure 65. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Figure 66. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Application (2021-2026)
Figure 67. Egypt RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 68. South Africa RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 69. Israel RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 70. Turkey RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 71. GCC Countries RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of RNA Therapeutics and Vaccines in 2026
Figure 73. Manufacturing Process Analysis of RNA Therapeutics and Vaccines
Figure 74. Industry Chain Structure of RNA Therapeutics and Vaccines
Figure 75. Channels of Distribution
Figure 76. Global RNA Therapeutics and Vaccines Sales Market Forecast by Region (2027-2032)
Figure 77. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Region (2027-2032)
Figure 78. Global RNA Therapeutics and Vaccines Sales Market Share Forecast by Type (2027-2032)
Figure 79. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Type (2027-2032)
Figure 80. Global RNA Therapeutics and Vaccines Sales Market Share Forecast by Application (2027-2032)
Figure 81. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of RNA Therapeutics and Vaccines
Figure 2. RNA Therapeutics and Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global RNA Therapeutics and Vaccines Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global RNA Therapeutics and Vaccines Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. RNA Therapeutics and Vaccines Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. RNA Therapeutics and Vaccines Sales Market Share by Country/Region (2025)
Figure 10. RNA Therapeutics and Vaccines Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of mRNA (messenger RNA) Therapeutics
Figure 12. Product Picture of siRNA (small interfering RNA) Therapeutics
Figure 13. Product Picture of Antisense Oligonucleotide Therapeutics
Figure 14. Global RNA Therapeutics and Vaccines Sales Market Share by Type in 2026
Figure 15. Global RNA Therapeutics and Vaccines Revenue Market Share by Type (2021-2026)
Figure 16. RNA Therapeutics and Vaccines Consumed in Hospitals
Figure 17. Global RNA Therapeutics and Vaccines Market: Hospitals (2021-2026) & (K Units)
Figure 18. RNA Therapeutics and Vaccines Consumed in Research Institutions
Figure 19. Global RNA Therapeutics and Vaccines Market: Research Institutions (2021-2026) & (K Units)
Figure 20. Global RNA Therapeutics and Vaccines Sale Market Share by Application (2025)
Figure 21. Global RNA Therapeutics and Vaccines Revenue Market Share by Application in 2026
Figure 22. RNA Therapeutics and Vaccines Sales by Company in 2026 (K Units)
Figure 23. Global RNA Therapeutics and Vaccines Sales Market Share by Company in 2026
Figure 24. RNA Therapeutics and Vaccines Revenue by Company in 2026 ($ millions)
Figure 25. Global RNA Therapeutics and Vaccines Revenue Market Share by Company in 2026
Figure 26. Global RNA Therapeutics and Vaccines Sales Market Share by Geographic Region (2021-2026)
Figure 27. Global RNA Therapeutics and Vaccines Revenue Market Share by Geographic Region in 2026
Figure 28. Americas RNA Therapeutics and Vaccines Sales 2021-2026 (K Units)
Figure 29. Americas RNA Therapeutics and Vaccines Revenue 2021-2026 ($ millions)
Figure 30. APAC RNA Therapeutics and Vaccines Sales 2021-2026 (K Units)
Figure 31. APAC RNA Therapeutics and Vaccines Revenue 2021-2026 ($ millions)
Figure 32. Europe RNA Therapeutics and Vaccines Sales 2021-2026 (K Units)
Figure 33. Europe RNA Therapeutics and Vaccines Revenue 2021-2026 ($ millions)
Figure 34. Middle East & Africa RNA Therapeutics and Vaccines Sales 2021-2026 (K Units)
Figure 35. Middle East & Africa RNA Therapeutics and Vaccines Revenue 2021-2026 ($ millions)
Figure 36. Americas RNA Therapeutics and Vaccines Sales Market Share by Country in 2026
Figure 37. Americas RNA Therapeutics and Vaccines Revenue Market Share by Country (2021-2026)
Figure 38. Americas RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Figure 39. Americas RNA Therapeutics and Vaccines Sales Market Share by Application (2021-2026)
Figure 40. United States RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 41. Canada RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 42. Mexico RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 43. Brazil RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 44. APAC RNA Therapeutics and Vaccines Sales Market Share by Region in 2026
Figure 45. APAC RNA Therapeutics and Vaccines Revenue Market Share by Region (2021-2026)
Figure 46. APAC RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Figure 47. APAC RNA Therapeutics and Vaccines Sales Market Share by Application (2021-2026)
Figure 48. China RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 49. Japan RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 50. South Korea RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 51. Southeast Asia RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 52. India RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 53. Australia RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 54. China Taiwan RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 55. Europe RNA Therapeutics and Vaccines Sales Market Share by Country in 2026
Figure 56. Europe RNA Therapeutics and Vaccines Revenue Market Share by Country (2021-2026)
Figure 57. Europe RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Figure 58. Europe RNA Therapeutics and Vaccines Sales Market Share by Application (2021-2026)
Figure 59. Germany RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 60. France RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 61. UK RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 62. Italy RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 63. Russia RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 64. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Country (2021-2026)
Figure 65. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Type (2021-2026)
Figure 66. Middle East & Africa RNA Therapeutics and Vaccines Sales Market Share by Application (2021-2026)
Figure 67. Egypt RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 68. South Africa RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 69. Israel RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 70. Turkey RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 71. GCC Countries RNA Therapeutics and Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of RNA Therapeutics and Vaccines in 2026
Figure 73. Manufacturing Process Analysis of RNA Therapeutics and Vaccines
Figure 74. Industry Chain Structure of RNA Therapeutics and Vaccines
Figure 75. Channels of Distribution
Figure 76. Global RNA Therapeutics and Vaccines Sales Market Forecast by Region (2027-2032)
Figure 77. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Region (2027-2032)
Figure 78. Global RNA Therapeutics and Vaccines Sales Market Share Forecast by Type (2027-2032)
Figure 79. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Type (2027-2032)
Figure 80. Global RNA Therapeutics and Vaccines Sales Market Share Forecast by Application (2027-2032)
Figure 81. Global RNA Therapeutics and Vaccines Revenue Market Share Forecast by Application (2027-2032)
